Wall Street analyst estimates for BriaCell Therapeutics Corp. (BCTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-06-09 | $-0.99 | ||
| 2026-03-10 | $-2.58 | $-4.84 | +46.7% |
| 2025-12-11 | $-4.35 | $-3.28 | -32.6% |
| 2025-10-27 | $-10.49 | $-12.11 | +13.4% |
| 2025-06-16 | $-1.64 | $-17.60 | +90.7% |
| 2025-03-12 | $-23.30 | $-19.40 | -20.1% |
| 2024-12-16 | $-32.98 | $-0.30 | -10893.3% |
| 2024-10-28 | $-0.07 | $-0.52 | +86.5% |
Valuation Ratios
| Price / Book | 1.06 |
| EV / EBITDA | -0.75 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1803 | $290 | $16877 | $18833 | $18735 | $15580 | $15139 | $15529 | $82573 | $147888 |
| Gross Profit | -$1803 | -$289 | -$16877 | -$18833 | -$18735 | -$15580 | -$15139 | -$15529 | -$82573 | -$147888 |
| Research & Development | $952150 | $2.1M | $3.1M | $4.9M | $3.0M | $2.5M | $10.3M | $20.5M | $27.2M | $29.5M |
| Selling, General & Admin | $1.2M | $1.1M | $1.8M | $1.3M | $1.8M | $6.2M | $9.3M | $10.6M | $6.2M | $8.1M |
| Operating Expenses | $2.2M | $3.2M | $5.0M | $6.2M | $4.8M | $8.7M | $19.6M | $31.1M | $33.3M | $37.6M |
| Operating Income | -$2.2M | -$3.2M | -$5.0M | -$6.3M | -$5.3M | -$8.7M | -$19.6M | -$31.1M | -$33.3M | -$37.7M |
| EBITDA | -$2.2M | -$3.2M | -$5.4M | -$5.8M | -$4.8M | -$17.1M | -$34.4M | -$31.1M | -$4.8M | -$37.6M |
| Interest Expense | 0 | 0 | $20344 | $31467 | $36204 | $100217 | $1244 | 0 | 0 | $51288 |
| Pre-tax Income | -$2.2M | -$3.2M | -$5.4M | -$5.8M | -$5.4M | -$17.3M | -$34.4M | -$27.1M | -$4.9M | -$36.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.2M | -$3.2M | -$5.4M | -$5.8M | -$4.9M | -$17.3M | -$34.4M | -$27.1M | -$4.8M | -$36.5M |
| EPS | $-1360.30 | $-1348.63 | $-1798.34 | $-1505.30 | $-5.64 | $-13.50 | $-257.58 | $-192.55 | $-43.01 | $-62.60 |
| EPS (Diluted) | $-1360.30 | $-1348.63 | $-1798.34 | $-1505.30 | $-5.64 | $-13.50 | $-259.50 | $-195.00 | $-43.01 | $-62.60 |
| Shares Outstanding (Diluted) | $19231 | $22647 | $28520 | $38644 | $47592 | $301305 | $1.0M | $1.0M | $1.1M | $1.9M |
Price
| Price | $3.56 |
| Market Cap | $31M |
| Exchange | NASDAQ |
| Country | CA |
Related companies: ALLR · ASBP · CRIS · CTXR · ENTO · HOTH · LPTX
Explore sector: Healthcare · Biotechnology
More sections of BCTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks